ERIS LIFESCIENCES
|
ERIS LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 28.10 | 29.88 | 26.16 | 21.84 | 21.15 |
| CEPS(Rs) | 36.12 | 34.61 | 29.32 | 25.54 | 23.81 |
| DPS(Rs) | 7.35 | 6.01 | 5.50 | 2.87 | - |
| Book NAV/Share(Rs) | 161.28 | 140.25 | 115.81 | 95.26 | 83.57 |
| Tax Rate(%) | 7.53 | 8.23 | 9.98 | 10.52 | 8.26 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 30.42 | 34.77 | 34.60 | 34.25 | 35.13 |
| EBIT Margin(%) | 24.42 | 32.00 | 31.85 | 31.06 | 34.66 |
| Pre Tax Margin(%) | 22.92 | 31.70 | 31.69 | 30.85 | 32.31 |
| PAT Margin (%) | 21.20 | 29.09 | 28.53 | 27.61 | 29.64 |
| Cash Profit Margin (%) | 27.83 | 33.73 | 31.98 | 32.29 | 33.34 |
| Performance Ratios | |||||
| ROA(%) | 13.40 | 21.27 | 22.62 | 20.33 | 20.02 |
| ROE(%) | 18.25 | 23.33 | 24.78 | 24.28 | 28.96 |
| ROCE(%) | 17.31 | 25.29 | 27.60 | 25.44 | 26.54 |
| Asset Turnover(x) | 0.63 | 0.73 | 0.79 | 0.74 | 0.68 |
| Sales/Fixed Asset(x) | 0.90 | 1.33 | 1.25 | 1.18 | 1.18 |
| Working Capital/Sales(x) | 5.49 | 3.26 | 4.15 | 3.41 | 3.56 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.11 | 0.75 | 0.80 | 0.85 | 0.84 |
| Receivable days | 46.91 | 39.44 | 43.59 | 40.93 | 27.99 |
| Inventory Days | 25.78 | 27.78 | 24.03 | 25.85 | 27.52 |
| Payable days | 125.63 | 155.58 | 155.23 | 195.95 | 207.67 |
| Valuation Parameters | |||||
| PER(x) | 20.36 | 23.06 | 23.11 | 16.88 | 30.46 |
| PCE(x) | 15.84 | 19.91 | 20.61 | 14.43 | 27.04 |
| Price/Book(x) | 3.55 | 4.91 | 5.22 | 3.87 | 7.71 |
| Yield(%) | 1.28 | 0.87 | 0.91 | 0.78 | - |
| EV/Net Sales(x) | 5.07 | 6.95 | 6.74 | 4.60 | 9.19 |
| EV/Core EBITDA(x) | 15.60 | 18.31 | 18.59 | 12.86 | 23.96 |
| EV/EBIT(x) | 19.84 | 20.97 | 20.60 | 14.79 | 26.51 |
| EV/CE(x) | 2.46 | 4.43 | 4.80 | 3.44 | 6.10 |
| M Cap / Sales | 4.62 | 6.95 | 6.77 | 4.66 | 9.02 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 25.10 | 11.15 | 12.83 | 9.36 | 14.79 |
| Core EBITDA Growth(%) | 7.23 | 16.31 | 14.47 | 1.89 | 8.11 |
| EBIT Growth(%) | -3.46 | 12.60 | 18.83 | -1.99 | 5.43 |
| PAT Growth(%) | -7.79 | 14.26 | 19.77 | 1.84 | -1.30 |
| EPS Growth(%) | -5.94 | 14.23 | 19.78 | 3.27 | -1.14 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.38 | 0.02 | - | - | 0.15 |
| Current Ratio(x) | 1.62 | 2.51 | 2.27 | 2.43 | 1.73 |
| Quick Ratio(x) | 1.41 | 2.16 | 1.95 | 2.12 | 1.51 |
| Interest Cover(x) | 16.36 | 105.81 | 200.75 | 145.25 | 14.76 |
| Total Debt/Mcap(x) | 0.11 | - | - | - | 0.02 |
Compare Financial Ratios of peers of ERIS LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ERIS LIFESCIENCES | ₹12,017.0 Cr | -0.7% | -3.9% | 48.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹369,402.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹109,341.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,341.0 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹99,176.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,543.1 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
ERIS LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ERIS LIFESCIENCES | -0.7% |
-3.9% |
48.8% |
| SENSEX | -0.8% |
1.4% |
22.9% |
You may also like the below Video Courses
